share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K:重大事件
美股SEC公告 ·  05/23 16:28
Moomoo AI 已提取核心信息
Exicure, Inc., a biotechnology company, has received a Staff Delisting Determination from the Nasdaq Listing Qualifications Department due to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company failed to file its annual report (Form 10-K) for the year ended December 31, 2023, by the extended deadline of May 20, 2024, and also did not file its quarterly report (Form 10-Q) for the first quarter of 2024. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders. As a result, Nasdaq plans to suspend trading of Exicure's common stock at the opening of business on May 30, 2024, unless the company files an appeal by May 28, 2024. Exicure intends to appeal the delisting and request a stay of suspension while it works to regain compliance. The company is actively working to complete and file the overdue reports and to hold a combined Annual Meeting for 2023 and 2024 as soon as possible. However, there is no assurance that Exicure will be able to regain compliance or be successful in its appeal to Nasdaq.
Exicure, Inc., a biotechnology company, has received a Staff Delisting Determination from the Nasdaq Listing Qualifications Department due to non-compliance with Nasdaq Listing Rule 5250(c)(1). The company failed to file its annual report (Form 10-K) for the year ended December 31, 2023, by the extended deadline of May 20, 2024, and also did not file its quarterly report (Form 10-Q) for the first quarter of 2024. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders. As a result, Nasdaq plans to suspend trading of Exicure's common stock at the opening of business on May 30, 2024, unless the company files an appeal by May 28, 2024. Exicure intends to appeal the delisting and request a stay of suspension while it works to regain compliance. The company is actively working to complete and file the overdue reports and to hold a combined Annual Meeting for 2023 and 2024 as soon as possible. However, there is no assurance that Exicure will be able to regain compliance or be successful in its appeal to Nasdaq.
生物技术公司Exicure, Inc. 因未遵守纳斯达克上市规则5250 (c) (1),已收到纳斯达克上市资格部门的员工退市决定。该公司未能在延长的截止日期(2024年5月20日)之前提交截至2023年12月31日止年度的年度报告(10-K表格),也没有提交2024年第一季度的季度报告(10-Q表格)。此外,Exicure尚未举行其2023年年度股东大会。因此,纳斯达克计划在2024年5月30日开业时暂停Exicure普通股的交易,除非该公司在2024年5月28日之前提出上诉。Exicure打算对除名提出上诉,并要求在努力恢复合规的同时暂缓停牌。该公司正在积极努力完成和提交逾期报告,并尽快举行2023年和2024年的合并年会。但是,无法保证Exicure能够恢复合规性或成功向纳斯达克提出上诉。
生物技术公司Exicure, Inc. 因未遵守纳斯达克上市规则5250 (c) (1),已收到纳斯达克上市资格部门的员工退市决定。该公司未能在延长的截止日期(2024年5月20日)之前提交截至2023年12月31日止年度的年度报告(10-K表格),也没有提交2024年第一季度的季度报告(10-Q表格)。此外,Exicure尚未举行其2023年年度股东大会。因此,纳斯达克计划在2024年5月30日开业时暂停Exicure普通股的交易,除非该公司在2024年5月28日之前提出上诉。Exicure打算对除名提出上诉,并要求在努力恢复合规的同时暂缓停牌。该公司正在积极努力完成和提交逾期报告,并尽快举行2023年和2024年的合并年会。但是,无法保证Exicure能够恢复合规性或成功向纳斯达克提出上诉。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息